arrow
C

Caroline Robert

institut gustave roussy
H指数:154
被引数:15.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

原发性黑色素瘤假阴性诊断患者的生命损失年数。一项涉及9063例患者、为期28年的德国中央恶性黑色素瘤登记研究的回顾性研究

2026-07-020
OAAI
Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA

西米普利单抗与历史全身治疗在局部晚期或转移性皮肤鳞状细胞癌中的比较:法国TOSCA研究的结果

2026-03-050
PRE
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

新辅助PD-1和LAG-3靶向双特异性抗体与其他免疫检查点抑制剂联合治疗可切除黑色素瘤:随机Ib/II期Morpheus-Melanoma试验

2025-09-240
OAAI
Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases

胶原性结肠炎在癌症治疗患者中的发生:免疫检查点抑制剂的潜在作用。15例患者的临床、组织学和免疫学特征

2025-08-060
OAAI
Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma.

新辅助病灶内靶向免疫细胞因子(Daromun)在III期黑色素瘤中的应用。

2025-07-070
PREAI
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial

新辅助抗PD-1单药或联合抗TIGIT或溶瘤病毒在可切除的III B-D期黑色素瘤中的应用:一项I/II期临床试验

2025-01-072
OA
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

皮肤黑色素瘤:ESMO 临床实践指南(用于诊断、治疗和随访)

2025-01-0111
PRE
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
2025-01-010
OAAI
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

EORTC1325/KEYNOTE-054试验中pembrolizumab与安慰剂在III期黑色素瘤中的七年分析

2024-11-012
PRE
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
2024-11-011
OAAI
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
2024-11-010
PRE
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

癌症药物耐受性持久细胞: 从生物学问题到临床机会

2024-09-020
PRE